S&P Futures
4,574.75 -2.00 (-0.04%) Dow Futures
36,031.00 +21.00 (+0.06%) Nasdaq Futures
15,960.00 -25.50 (-0.16%) Russell 2000 Futures
1,814.80 +2.60 (+0.14%) Crude Oil
75.89 -0.07 (-0.09%) Gold
2,061.50 +4.30 (+0.21%)
Apellis Pharmaceuticals, Inc. (APLS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 50.30 |
| Open | 50.52 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 2900 |
| Day's Range | 50.52 - 54.96 |
| 52 Week Range | 19.83 - 94.75 |
| Volume | |
| Avg. Volume | 2,291,862 |
| Market Cap | 6.384B |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.23 |
| Earnings Date | Feb 19, 2024 - Feb 23, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.19 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APLS
Related Research
- Apellis Pharmaceuticals, Inc.Analyst Report: argenx SEArgenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.RatingFair ValueEconomic Moat3 days agoMorningstar
Simply Wall St.Apellis Pharmaceuticals' (NASDAQ:APLS) growing losses don't faze investors as the stock rises 5.6% this past week
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abo
ZacksJazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.
